<DOC>
	<DOCNO>NCT01016262</DOCNO>
	<brief_summary>Hypothesis : The responder rate MAX-002 superior placebo 6 week treatment patient mild moderate ulcerative proctitis . Summary : The primary purpose study evaluate efficacy safety new mesalamine suppository ( MAX-002 ) compare placebo 6 week treatment adult mild moderate ulcerative proctitis . Prior randomization , inclusion exclusion criterion verify confirm eligibility . Patients find eligible randomized 1:1:1 scheme receive either MAX-002 1 g , CanasaÂ® 1 g , Placebo suppository daily bedtime 6 week double-blind fashion . Completers Study Week 6 offer receive MAX-002 1 g suppository voluntary basis next 8 week open-label phase . Regardless treatment group , patient evaluate phone call Study Weeks 1 2 follow clinical visit Study Weeks 3 , 6 , 14 . Study-specific procedure include limited following : flexible proctosigmoidoscopy ; disease activity assessment ; smoke habit description ; health-related quality life ; compliance treatment check safety evaluation ( physical examination , ECG , vitals sign , clinical laboratory analysis ) . All patient complete daily diary ask general open question occurrence adverse events/concurrent medical condition , use adjunctive therapy/procedure , intake concomitant medication .</brief_summary>
	<brief_title>Efficacy Safety Study MAX-002 Suppository Versus Placebo Mild Moderate Ulcerative Proctitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Proctitis</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Main At screening , patient must confirmation mild moderate UP extend rectum total Mayo DAI score 5 10 , inclusively . Score 2 `` Rectal bleeding '' `` Findings flexible proctosigmoidoscopy colonoscopy '' subscores Mayo DAI . Main Presence digestive disease interfere measurement subscore DAI . Known presence suspicion malignant disease digestive system presence history neoplasms carcinoma situ cervix basal carcinoma skin . Chronic use oral 5aminosalicylic acid ( 5ASA ) dose great 4 g daily , change oral 5ASA dosing , use form rectal 5ASA formulation 30 day prior randomization . Significant use corticosteroid may therapeutic effect UP , immunosuppressant biologic response modifier 45 day prior date consent . Use rectally administer medicine 30 day prior randomization . Presence know clinically significant medical and/or psychological illness preclude participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Ulcerative proctitis</keyword>
	<keyword>Proctocolitis</keyword>
	<keyword>Inflammatory Bowel Disease</keyword>
	<keyword>Gastrointestinal Diseases</keyword>
	<keyword>Colonic Diseases</keyword>
	<keyword>Mesalamine</keyword>
	<keyword>5-ASA</keyword>
</DOC>